惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

G
Google Developers Blog
GbyAI
GbyAI
Y
Y Combinator Blog
The GitHub Blog
The GitHub Blog
B
Blog
博客园 - 叶小钗
V
Visual Studio Blog
小众软件
小众软件
阮一峰的网络日志
阮一峰的网络日志
博客园 - 聂微东
S
SegmentFault 最新的问题
Engineering at Meta
Engineering at Meta
博客园 - Franky
V
V2EX
人人都是产品经理
人人都是产品经理
H
Hackread – Cybersecurity News, Data Breaches, AI and More
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
月光博客
月光博客
IT之家
IT之家
T
The Blog of Author Tim Ferriss
奇客Solidot–传递最新科技情报
奇客Solidot–传递最新科技情报
C
Check Point Blog
N
Netflix TechBlog - Medium
博客园 - 【当耐特】

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call Tra...
2026-05-14 · via All Articles on Seeking Alpha

Q1: 2026-05-13 Earnings Summary

EPS of -$0.30 beats by $0.09

 | 

Revenue of

$8.72M

beats by $3.78M

Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call May 13, 2026 8:30 AM EDT

Company Participants

Joseph Vazzano - Chief Financial Officer
Vishwas Seshadri - President, CEO & Director
Madhav Vasanthavada - Chief Commercial Officer

Conference Call Participants

Kristen Kluska - Cantor Fitzgerald & Co., Research Division
Maurice Raycroft - Jefferies LLC, Research Division
Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division
Jeffrey Jones - Oppenheimer & Co. Inc., Research Division
James Molloy - Alliance Global Partners, Research Division
David Bautz - Zacks Small-Cap Research

Presentation

Operator

Good day, ladies and gentlemen, and welcome to the Abeona Therapeutics First Quarter 2026 Earnings Conference Call.

[Operator instructions].

And please note, this conference is being recorded. I will now turn the conference over to your host, Mr. Joe Vazzano, Chief Financial Officer of Abeona Therapeutics. Sir, the floor is yours.

Joseph Vazzano
Chief Financial Officer

Thank you, operator. Good morning, and thank you for joining us on our first quarter 2026 results and business update conference call.

During this call, we will refer to the press release issued this morning announcing the financial results, which is available on our corporate website at www.abeonatherapeutics.com.

We anticipate making projections and forward-looking statements during today's call, which are made pursuant to the safe harbor provisions of the federal securities laws.

These forward-looking statements are based on current expectations and are subject to change. Actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including, but not limited to, those outlined in our Form 10-K and periodic reports filed with the Securities and Exchange Commission.

These documents are available on our website at www.avonathapeutics.com.

Joining me on today's call with prepared remarks are Dr. Vishwas Seshadri, Chief Executive Officer; and Dr.Madhav Vasanthavada , Chief Commercial Officer.

With that, I will now turn